Thymosin α1 interacts with Galectin-1 modulating the β-galactosides affinity and inducing alteration in the biological activity.

Angiogenesis Cancer Galectin-1 Mechanism of action Molecular interaction Pleiotropism

Journal

International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259

Informations de publication

Date de publication:
May 2023
Historique:
received: 31 01 2023
revised: 17 03 2023
accepted: 18 03 2023
medline: 25 4 2023
pubmed: 8 4 2023
entrez: 7 4 2023
Statut: ppublish

Résumé

The study of mechanism of action of Thymosin alpha 1 (Tα1) and the basis of the pleiotropic effect in health and disease, is one of the main focus of our ongoing research. Tα1 is a thymic peptide that demonstrates a peculiar ability to restore homeostasis in different physiological and pathological conditions (i.e., infections, cancer, immunodeficiency, vaccination, and aging) acting as multitasking protein depending on the host state of inflammation or immune dysfunction. However, few are the information about mechanisms of action mediated by specific Tα1-target protein interaction that could explain its pleiotropic effect. We investigated the interaction of Tα1 with Galectin-1 (Gal-1), a protein belonging to an oligosaccharide binding protein family involved in a variety of biological and pathological processes, including immunoregulation, infections, cancer progression and aggressiveness. Using molecular and cellular methodological approaches, we demonstrated the interaction between these two proteins. Tα1 specifically inhibited the hemagglutination activity of Gal-1, the Gal-1 dependent in vitro formation of endothelial cell tubular structures, and the migration of cancer cells in wound healing assay. Physico-chemical methods revealed the details of the molecular interaction of Tα1 with Gal-1. Hence, the study allowed the identification of the not known until now specific interaction between Tα1 and Gal-1, and unraveled a novel mechanism of action of Tα1 that could support understanding of its pleiotropic activity.

Identifiants

pubmed: 37028279
pii: S1567-5769(23)00434-4
doi: 10.1016/j.intimp.2023.110113
pii:
doi:

Substances chimiques

Thymalfasin W0B22ISQ1C
Thymosin 61512-21-8
beta-galactoside 0
Galectin 1 0
1-nitrohydroxyphenyl-N-benzoylalanine 59921-69-6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110113

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Claudia Matteucci (C)

Department of Experimental Medicine, University of Tor Vergata, Rome 00133, Italy. Electronic address: matteucci@med.uniroma2.it.

Ridvan Nepravishta (R)

Department of Chemical Sciences and Technologies, University of Rome "Tor Vergata", Rome 00133, Italy.

Ayele Argaw-Denboba (A)

Department of Experimental Medicine, University of Tor Vergata, Rome 00133, Italy; European Molecular Biology Laboratory, EMBL, Monterotondo, Rome 00015, Italy.

Walter Mandaliti (W)

Department of Chemical Sciences and Technologies, University of Rome "Tor Vergata", Rome 00133, Italy.

Alessandro Giovinazzo (A)

Department of Experimental Medicine, University of Tor Vergata, Rome 00133, Italy; Institute of Biochemistry and Cell Biology, IBBC-CNR, Monterotondo, Rome 00015, Italy.

Vita Petrone (V)

Department of Experimental Medicine, University of Tor Vergata, Rome 00133, Italy.

Emanuela Balestrieri (E)

Department of Experimental Medicine, University of Tor Vergata, Rome 00133, Italy.

Paola Sinibaldi-Vallebona (P)

Department of Experimental Medicine, University of Tor Vergata, Rome 00133, Italy; Institute of Translational Pharmacology, National Research Council, Rome 00133, Italy.

Francesca Pica (F)

Department of Experimental Medicine, University of Tor Vergata, Rome 00133, Italy.

Maurizio Paci (M)

Department of Chemical Sciences and Technologies, University of Rome "Tor Vergata", Rome 00133, Italy.

Enrico Garaci (E)

IRCCS San Raffaele and IRCCS San Raffaele, Rome 00163, Italy; Medical and Experimental BioImaging Center, MEBIC Consortium, Rome 00166, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH